Epistem opens US laboratory in Baltimore

Published: 4-Mar-2014
Research & Development Pharmaceutical

Currently offers histology and immunohistochemistry (IHC) services


Epistem, a biotechnology and personalised medicine company based in Manchester, UK, has opened a US laboratory in Baltimore, Maryland to support the expansion of its contract research division within the US.

The Baltimore laboratory is currently offering histology and immunohistochemistry (IHC) services, expanding on the success of the GcLP and GLP compliant UK laboratory. The technical team has already developed IHC protocols for a panel of more than 150 antibodies which are available worldwide.

Catherine Booth, Co-Founder of Epistem and Director of the Contract Services Business, said: 'Epistem's specialist contract research services provide valuable support to drug discovery and development pipelines. We already have strong relationships with both companies, academic and government groups on the East Coast along with a US Business team based in Boston and Baltimore. We are excited to now be providing services locally to support this growing US business.'

  • Companies:
  • Epistem
See more

You may also like

Research & Development

UK-Norwegian team to develop living skin equivalent testing model

Read more
For testing inflammatory responses

Trending Articles

  1. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  2. Anton Paar expands Litesizer DIA Series with new models Introducing affordable and advanced solutions for particle analysis
  3. 2BScientific expands its life science product supply service to Europe with new German facility The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
  4. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  5. Five critical design elements for Pelton wheel turbine flowmeters Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

UK-Norwegian team to develop living skin equivalent testing model

For testing inflammatory responses
Research & Development

Epistem announces three-year collaboration with GSK

Will apply RND-Amp technology to fibrosis research
Research & Development

Epistem signs three-year research deal with sanofi-aventis

Will provide discovery through to clinical biomarker support to sanofi-aventis oncology programmes
Research & Development

Epistem awarded US$3.5m in NIH biodefence contract

Consortium is developing drugs to treat radiation damage to the gastrointestinal tract
Manufacturing

Veritas becomes exclusive distributor in Japan for Epistem

Will enable Epistem to extend its research services in the region
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Subscribe now